Project: XZ.700: targeted antibacterial endolysin to treat infected diabetic wounds
| Acronym | Lyse-EFEKT (Reference Number: 113238) |
| Duration | 01/10/2019 - 03/04/2022 |
| Project Topic | The consortium will develop a targeted antibacterial endolysin product to treat diabetic wounds (DWs) infected with S. aureus or methicillin-resistant S. aureus (MRSA). First, an appropriate XZ.700 containing formulation will be developed and pre-clinical safety and efficacy will be validated for the treatment of S. aureus-infected DWs. At the end, a suitable formulation containing XZ.700 will be ready for clinical development and used to enter a license deal with a pharmaceutical company. |
| Network | Eurostars 2 |
| Call | Eurostars Cut–off 11 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | Micreos Human Health BV | Partner | Netherlands |
| 2 | VitroScreen S.r.L. | Partner | Italy |
| 3 | ATLANGRAM | Partner | France |